You are here

Positive 2-Year Results Reported for Investigational Low-Back Pain Injections

Study evaluates mesenchymal precursor cell product

Positive 24-month results from a phase II program for chronic low-back pain have been presented at the JP Morgan 33rd Annual Healthcare Conference, being held in San Francisco, California.

 In a randomized, placebo-controlled, phase II study involving 100 patients with chronic low-back pain due to degenerative disc disease, a single injection of an allogeneic investigational mesenchymal precursor cell (MPC) product, MPC-06-ID (Mesoblast Limited), was well tolerated and was shown to result in substantial improvement in pain and function for at least 24 months.

Highlights of the clinical results include the following:

•     A single injection of 6 million MPCs induced substantial and sustained pain relief over 24 months. At 12 and 24 months, 46% and 48% of patients treated with MPC-06-ID achieved minimal or no residual pain (Visual Analog Scale score of 20 or less) compared with 13% of saline-treated patients (P = 0.042 and P = 0.093) , respectively.

•     In patients who received a single injection of 6 or 18 million MPCs, 44% and 42%, respectively, achieved the target composite endpoint of treatment success (50% reduction in pain, 15-point improvement in function, and no further treatment intervention) at both 6 and 12 months compared with 13% of saline controls (P = 0.006 and P = 0.020), respectively.

•     In patients who received 6 million MPCs and achieved the target composite endpoint of treatment success at both 6 and 12 months, 86% (11 of 13) maintained treatment success at 24 months (32% vs. 11% saline controls; P = 0.001).

More than 4 million individuals in the U.S. have chronic low-back pain. The total costs of low-back pain are estimated to be between $100 billion and $200 billion annually, with two thirds of the costs attributed to patients’ decreased wages and productivity.

Source: Mesoblast Limited; January 15, 2015.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens